Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib
Dasatinib is a second-generation multi-target tyrosine kinase inhibitor (TKI) that has activity against many imatinib-resistant BCR-ABL mutant forms, Src, and c-Kit tyrosine kinases. While skin hypopigmentation is a well recognized adverse effect of first generation TKIs; it has rarely been report...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2014-11-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/5160/8055_CE(Ra)_F(Sh)_PF1(AJAK)_PFA(Sh).pdf |
| _version_ | 1818832311470260224 |
|---|---|
| author | Karim Boudadi Rashmi Chugh |
| author_facet | Karim Boudadi Rashmi Chugh |
| author_sort | Karim Boudadi |
| collection | DOAJ |
| description | Dasatinib is a second-generation multi-target tyrosine kinase inhibitor (TKI) that has activity against many imatinib-resistant BCR-ABL
mutant forms, Src, and c-Kit tyrosine kinases. While skin hypopigmentation is a well recognized adverse effect of first generation TKIs; it
has rarely been reported with dasatinib. We report a unique case of diffuse cutaneous hypopigmentation induced by dasatinib followed by
hyperpigmentation occurring in the same patient. A 52-year-old African American female with a history of metastatic hemangiopericytoma
was initiated on dasatinib as part of a clinical trial. After 2 months of treatment, she developed generalized skin hypopigmentation. Within
1 month of discontinuing the drug, the patient’s skin pigmentation returned to normal. However, she then developed diffuse skin hyperpigmentation over the next couple of months. The hyperpigmentation was self-limited, and eventually resolved after several months. |
| first_indexed | 2024-12-19T02:01:01Z |
| format | Article |
| id | doaj.art-2616d01c43214782a7ddcce5d184f3bd |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-19T02:01:01Z |
| publishDate | 2014-11-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-2616d01c43214782a7ddcce5d184f3bd2022-12-21T20:41:03ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2014-11-01811QD01QD0210.7860/JCDR/2014/8055.5160Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with DasatinibKarim Boudadi0Rashmi Chugh1Clinical Lecturer, Division of General Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.Assistant Professor, Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.Dasatinib is a second-generation multi-target tyrosine kinase inhibitor (TKI) that has activity against many imatinib-resistant BCR-ABL mutant forms, Src, and c-Kit tyrosine kinases. While skin hypopigmentation is a well recognized adverse effect of first generation TKIs; it has rarely been reported with dasatinib. We report a unique case of diffuse cutaneous hypopigmentation induced by dasatinib followed by hyperpigmentation occurring in the same patient. A 52-year-old African American female with a history of metastatic hemangiopericytoma was initiated on dasatinib as part of a clinical trial. After 2 months of treatment, she developed generalized skin hypopigmentation. Within 1 month of discontinuing the drug, the patient’s skin pigmentation returned to normal. However, she then developed diffuse skin hyperpigmentation over the next couple of months. The hyperpigmentation was self-limited, and eventually resolved after several months.https://jcdr.net/articles/PDF/5160/8055_CE(Ra)_F(Sh)_PF1(AJAK)_PFA(Sh).pdfsarcomaskin pigmentationtyrosine kinase inhibitor (tki) |
| spellingShingle | Karim Boudadi Rashmi Chugh Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib Journal of Clinical and Diagnostic Research sarcoma skin pigmentation tyrosine kinase inhibitor (tki) |
| title | Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib |
| title_full | Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib |
| title_fullStr | Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib |
| title_full_unstemmed | Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib |
| title_short | Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib |
| title_sort | diffuse hypopigmentation followed by hyperpigmentation in an african american woman with hemangiopericytoma treated with dasatinib |
| topic | sarcoma skin pigmentation tyrosine kinase inhibitor (tki) |
| url | https://jcdr.net/articles/PDF/5160/8055_CE(Ra)_F(Sh)_PF1(AJAK)_PFA(Sh).pdf |
| work_keys_str_mv | AT karimboudadi diffusehypopigmentationfollowedbyhyperpigmentationinanafricanamericanwomanwithhemangiopericytomatreatedwithdasatinib AT rashmichugh diffusehypopigmentationfollowedbyhyperpigmentationinanafricanamericanwomanwithhemangiopericytomatreatedwithdasatinib |